Safety, activity, and long-term outcomes of pomalidomide in the treatment of Kaposi sarcoma among individuals with or without HIV infection.
Ramya RamaswamiMark N PolizzottoKathryn LurainKathleen M WyvillAnaida WidellJomy GeorgePriscila GoncalvesSeth M SteinbergNazzarena LaboThomas S UldrickRobert YarchoanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Pomalidomide is a safe and active chemotherapy-sparing agent for the treatment of KS among individuals with or without HIV.